Xu Jiating, Wu Jiajia, Wang Xiaojing, Chen Qianqian, Xu Ruizhi, Xu Yaoyan, Geng Xiuchao, Tang Yiping
Psychosomatic Department, Taizhou Second People's Hospital, School of Medicine, Taizhou University, Taizhou, Zhejiang, 318000, China.
BMC Psychiatry. 2025 Feb 25;25(1):176. doi: 10.1186/s12888-025-06624-7.
To explore the efficacy of short-term trauma stabilization techniques combined with escitalopram in the treatment of adolescent major depressive disorder (MDD).
A total of 80 patients with MDD who were hospitalized in the Psychosomatic Department of our hospital were selected and randomly divided into two groups: the escitalopram combined with short-term trauma stabilization technique group (study group) and the escitalopram combined with mental health education group (control group). Upon hospitalization, patients completed the adolescent self-rating life events check list (ASLEC), impact of event scale-revised (IES-R), 17-item Hamilton depression scale (HAMD-17) and Hamilton anxiety scale (HAMA). After 2 and 4 weeks of treatment, the IES-R, HAMD-17-17 and HAMA scores were reevaluated.
There were no significant differences in the ASLEC, IES-R, HAMD-17 or HAMA scores between the two groups at admission. Compared with that of the control group, the IES-R score of the study group was significantly improved at the 2nd week of treatment (P < 0.01). By the 4th week of treatment, the IES-R scores in the study group had further improved compared to the control group (P < 0.01). Additionally, the HAMD-17 and HAMA scores in the study group were significantly improved compared to the control group (P < 0.01).
Escitalopram combined with short-term trauma stabilization is more effective in the treatment of MDD than escitalopram with mental health education, warranting further exploration.
探讨短期创伤稳定技术联合艾司西酞普兰治疗青少年重度抑郁症(MDD)的疗效。
选取我院心身科住院的80例MDD患者,随机分为两组:艾司西酞普兰联合短期创伤稳定技术组(研究组)和艾司西酞普兰联合心理健康教育组(对照组)。患者入院时完成青少年自评生活事件量表(ASLEC)、事件影响量表修订版(IES-R)、17项汉密尔顿抑郁量表(HAMD-17)和汉密尔顿焦虑量表(HAMA)。治疗2周和4周后,重新评估IES-R、HAMD-17和HAMA评分。
两组入院时ASLEC、IES-R、HAMD-17或HAMA评分无显著差异。与对照组相比,研究组治疗第2周时IES-R评分显著改善(P<0.01)。到治疗第4周时,研究组的IES-R评分与对照组相比进一步改善(P<0.01)。此外,研究组的HAMD-17和HAMA评分与对照组相比显著改善(P<0.01)。
艾司西酞普兰联合短期创伤稳定技术治疗MDD比艾司西酞普兰联合心理健康教育更有效,值得进一步探索。